Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 5 | Molecular Pain

Fig. 5

From: Pain perception in acute model mice of Parkinson’s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

Fig. 5

Quantitative analysis of astroglial and microglial activation to MPTP treatment in the spinal cord. a Comparison of GFAP-immunopositive astrocytes in the dorsal horn of the lumbar spinal cord between saline- and MPTP-treated mice (scale bars = 200 μm). b Saline- and MPTP-treated mice showed no difference in the number of astrocytes in the spinal cord (n = 4 per group, unpaired t-test). c Comparison of Iba1-immunopositive microglia in the dorsal and ventral horn of the lumbar spinal cord between saline- and MPTP-treated mice (scale bars = 200 μm). d Saline- and MPTP-treated mice showed no difference in the number of microglial cells in the spinal cord (n = 4 per group, unpaired t-test). e Comparison of TH-immunopositive neurons (red arrows) in the ventral horn of the lumbar spinal cord between saline- and MPTP-treated mice (scale bars = 200 μm). f Saline- and MPTP-treated mice showed no difference in the number of TH-positive neurons in the spinal cord (n = 4 per group, unpaired t-test)

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us